Revenue: As of FY2026 Q2, the actual value is USD 418.76 M, beating the estimate of USD 417.54 M.

EPS: As of FY2026 Q2, the actual value is USD 0.06.

EBIT: As of FY2026 Q2, the actual value is USD 23.47 M.

Operational Metrics

• Total reported revenues for the second quarter of 2026 were $418.8 million, an increase of 0.8% on a reported basis and 0.7% on an organic basis compared to the prior year.
• GAAP gross margin was 52.5% in the second quarter of 2026, up from 50.4% in the second quarter of 2025.
• Adjusted gross margin increased to 61.3% from 60.7% in the prior year.
• Operating income for the three months ended June 30, 2026, was $19,285 thousand, a significant improvement from an operating loss of - $512,674 thousand in the same period of 2025.
• GAAP net income for the second quarter of 2026 was $4.5 million, or $0.06 per diluted share, compared to a GAAP net loss of - $484.1 million, or - $6.31 per diluted share, in the prior year.
• Adjusted net income was $43.7 million, or $0.56 per diluted share, up from $34.4 million, or $0.45 per diluted share, in the prior year.
• Adjusted EBITDA for the second quarter of 2026 was $78.4 million, representing 18.7% of revenue, compared to $71.2 million, or 17.1% of revenue, in the prior year.
• Total costs and expenses decreased to $399,476 thousand in the second quarter of 2026 from $928,279 thousand in the second quarter of 2025.
• Cost of goods sold was $199,017 thousand in Q2 2026 compared to $206,273 thousand in Q2 2025.
• Research and development expenses were $24,253 thousand in Q2 2026, down from $26,997 thousand in Q2 2025.
• Selling, general and administrative expenses also decreased to $172,436 thousand from $179,890 thousand year-over-year.

Segment Revenue

• Specialty Surgery: Total revenues reached $309.3 million, showing a reported growth of 1.7% and an organic growth of 1.6% compared to the second quarter of 2025.
  • Neurosurgery sales increased by 1.9% on an organic basis.
  • Instruments sales grew by 3.2% on an organic basis.
  • ENT sales declined by -1.9%.
• Tissue Reconstruction: Total revenues were $109.5 million, experiencing reported and organic declines of -1.9% and -2.0%, respectively, compared to the second quarter of 2025.
  • Wound reconstruction saw a mid-single digit decline.
  • Private label sales grew by 4.7%.

Cash Flow

• Cash flow from operations was $22.8 million during the second quarter of 2026.
• Net cash provided by operating activities for the six months ended June 30, 2026, was $32,605 thousand, compared to net cash used in operating activities of - $2,338 thousand in the same period of 2025.
• Free cash flow for the second quarter was $10,495 thousand, an improvement from - $11,227 thousand in the prior year.

Debt Metrics

• Net debt was $1.6 billion as of the end of the quarter.
• The consolidated total leverage ratio was 4.1x.
• Total liquidity stood at approximately $496 million, including $274.1 million in cash and short-term investments.

Outlook / Guidance

Integra LifeSciences Holdings Corporation updated its full-year 2026 reported revenue guidance range to $1.654 billion to $1.695 billion, while reaffirming its full-year organic revenue growth guidance of 0.8% to 3.3% and adjusted earnings per share guidance of $2.40 to $2.50. For the third quarter of 2026, reported revenues are expected to range from $410 million to $425 million, with adjusted EPS between $0.53 and $0.61 per share. The company did not provide reconciliations to comparable GAAP financial measures for its forward-looking guidance due to the high variability and unpredictability of certain GAAP expense items and foreign exchange rates.